Comparison

Liraglutide vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	VK2735
Germany	Prescription	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Liraglutide and VK2735?: Liraglutide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or VK2735?: The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and VK2735 in Germany and the United States?: Germany: Liraglutide — Prescription, VK2735 — Unapproved. United States: Liraglutide — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

VK2735

Germany

Prescription

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Liraglutide and VK2735?

Liraglutide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or VK2735?

The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and VK2735 in Germany and the United States?

Germany: Liraglutide — Prescription, VK2735 — Unapproved. United States: Liraglutide — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.